Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Withdrawn
Trial end date:
2011-05-04
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo
in adolescent subjects (13-17 years of age inclusive) with ADHD in the analog classroom
setting based on the Permanent Product Measure of Performance (PERMP) total score assessed
across 2, 4, 9, 13, 14, and 15 hours post-dose on the last day of each double-blind crossover
period.